Please ensure Javascript is enabled for purposes of website accessibility

Why AnaptysBio Trounced the Market on Thursday

By Eric Volkman - Updated Feb 11, 2021 at 7:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech got a sharp upward shift in recommendation and target price from a prominent analyst.

What happened

AnaptysBio (ANAB 2.60%) rose by just over 11% on Thursday, as a high-profile bank has become more optimistic on the stock, to put it lightly.

So what

J.P. Morgan analyst Anupam Rama upgraded his recommendation on AnaptysBio stock. In his estimation, it's now overweight (i.e., buy), from the previous underweight (sell). The analyst also more than doubled his price target on the shares to $40; it was formerly $19.

Gloved and masked medical researchers using microscopes in their work.

Image source: Getty Images.

Rama is basing his enthusiasm on the company's upcoming official data release for its phase 2 clinical trial of imsidolimab. This drug aims to treat moderate to severe generalized palmoplantar pustulosis (GPP), a rare autoimmune disease that produces blisters on the palms of the hands or the soles of the feet. There is currently no cure for the condition; only management therapies are available. 

Preliminary results published last year from the imsidolimab trial indicate that it was efficacious in reducing the blisters in affected patients -- six out of eight participants collectively saw 94% clearance by day 29 after being administered the drug.

Now what

The fortunes of biotech companies depend on the performance of their medications in clinical trials. Rama's new confidence in AnaptysBio is striking. If imsidolimab continues to perform as well as indicated, it has a clear path to regulatory approval and success as the only robust GPP drug on the market.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AnaptysBio Stock Quote
$20.88 (2.60%) $0.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.